SARS‐CoV‐2 Activated Peripheral Blood Mononuclear Cells (PBMCs) Do Not Provoke Adverse Effects in Trophoblast Spheroids
American Journal of Reproductive Immunology · 2025
DOI: 10.1111/aji.70039 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Reproductive Immunology, 2025. Verfasst von Humblenoble Stembridge Ayuk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Environmental Immunology, Helmholtz Centre for Environmental Research, Leipzig, Saxony, Germany. Hauptthemen laut MEDLINE: Trophoblasts, Leukocytes, Mononuclear, COVID-19, SARS-CoV-2. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helmholtz-Gemeinschaft.
Abstract (Originalsprache)
Problem Although it is still uncertain whether Severe Acute Respiratory Coronavirus (SARS‐CoV‐2) placental infection and vertical transmission occur, inflammation during early pregnancy can have devastating consequences for gestation itself and the growing fetus. If and how SARS‐CoV‐2‐specific immune cells negatively affect placenta functionality is still unknown. Method of study We stimulated peripheral blood mononuclear cells (PBMCs) from women of reproductive age with SARS‐CoV‐2 peptides and cocultured them with trophoblast spheroids (HTR‐8/SVneo and JEG‐3) to dissect if SARS‐CoV‐2‐activated immune cells can interfere with trophoblast functionality. The activation and cytokine profile of the PBMCs were determined using multicolor flow cytometry. The functionality of trophoblast spheroids was assessed using microscopy, enzyme‐linked immunosorbent assay (ELISA), and RT‐qPCR.
Results
SARS‐CoV‐2 S and M peptides significantly activated PBMCs (monocytes, NK cells, and T cells with memory subsets) and induced the upregulation of proinflammatory cytokines, such as IFNγ. The activated PBMCs did not impact the viability, growth rate, and invasion capabilities of trophoblast spheroids. Furthermore, the hormonal production of hCG by JEG‐3 spheroids was not compromised upon coculture with the activated PBMCs. mRNA transcript levels of genes involved in trophoblast spheroid functional pathways were also not dysregulated after coculture.
Conclusions
Together, the findings of our in vitro coculture model, although not fully representative of in vivo conditions, strongly support the claim that the interaction of SARS‐CoV‐2‐activated peripheral blood immune cells with trophoblast cells at the fetal–maternal interface does not negatively affect trophoblast functionality. This goes in hand with the recommendation of vaccinating pregnant women in their first trimester.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Environmental Immunology, Helmholtz Centre for Environmental Research, Leipzig, Saxony, Germany.
- Saxon Incubator for Translational Research, University of Leipzig, Leipzig, Saxony, Germany.
- German Center for Child and Adolescent Health (DZKJ), Partner Site Leipzig/Dresden, Leipzig/Dresden, Germany.
ORCID-Profile: Humblenoble Stembridge Ayuk, Ana Claudia Zenclussen
Förderung
- Helmholtz-Gemeinschaft
Zitieren
APA
Ayuk, H. S., Arnold, S., Pierzchalski, A., Bauer, M., Stojanovska, V., & Zenclussen, A. C. (2025). SARS‐CoV‐2 Activated Peripheral Blood Mononuclear Cells (PBMCs) Do Not Provoke Adverse Effects in Trophoblast Spheroids. American Journal of Reproductive Immunology. https://doi.org/10.1111/aji.70039
Vancouver
Ayuk HS, Arnold S, Pierzchalski A, Bauer M, Stojanovska V, Zenclussen AC. SARS‐CoV‐2 Activated Peripheral Blood Mononuclear Cells (PBMCs) Do Not Provoke Adverse Effects in Trophoblast Spheroids. American Journal of Reproductive Immunology. 2025. doi:10.1111/aji.70039
BibTeX
@article{Ayuk2025,
author = {Ayuk, Humblenoble Stembridge and Arnold, Susanne and Pierzchalski, Arkadiusz and Bauer, Mario and Stojanovska, Violeta and Zenclussen, Ana Claudia},
title = {SARS‐CoV‐2 Activated Peripheral Blood Mononuclear Cells (PBMCs) Do Not Provoke Adverse Effects in Trophoblast Spheroids},
journal = {American Journal of Reproductive Immunology},
year = {2025},
doi = {10.1111/aji.70039}
}
EUVIMED